
On the same day that New York researchers received the top honor at the RSNA meeting for their poster detailing the benefits of an infection imaging agent, the drug's maker issued a warning about two deaths and additional serious adverse events attributed to its use. The admonition was released by Tyco Mallinckrodt Healthcare, which markets NeutroSpec (technetium-99m fanolesomab), a monoclonal antibody-labeled radiopharmaceutical agent approved in the U.S. for the diagnosis of equivocal appendicitis.







